Skip to main content

Advertisement

SpringerLink
Log in

Adiponectin and the cardiovascular system: from risk to disease

  • Review
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Adiponectin is known to play a role in fatty acid and glucose metabolism through a change in insulin sensitivity and activation of fuel oxidation by AMP-activated protein kinase. Adiponectin can be considered an important factor able to modulate the adipovascular axis which, through genomic and environmental influences, affects the cardiovascular risk milieu, from the pre-metabolic syndrome — through the metabolic syndrome — to the overt atherosclerotic process and its clinical manifestations. Hypoadiponectinaemia can be viewed as an early sign of a complex cardiovascular risk factor predisposing to the atherosclerosis process as well as a contributing factor accelerating the progress of the atherosclerotic plaque. In addition, adiponectin per se holds a protective role thanks to its anti-inflammatory and antiatherogenic properties. The early identification of patients “at cardiovascular risk” means in the current practice to search for indexes of metabolic derangements and pro-inflammatory status (adiponectin) from adolescence and childhood.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Matsuzawa Y (2005) White adipose tissue and cardiovascular disease. Best Pract Res Clin Endocrinol Metab 19:637–647

    Article  PubMed  CAS  Google Scholar 

  2. Zimmet P, Magliano D, Matsuzawa Y et al (2005) The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 12:295–300

    PubMed  CAS  Google Scholar 

  3. Maeda K, Okubo K, Shimomura I et al (1997) Analysis of an expression profile of genes in the human adipose tissue. Gene 190:227–235

    Article  PubMed  CAS  Google Scholar 

  4. Maeda K, Okubo K, Shimomura I et al (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286–289

    Article  PubMed  CAS  Google Scholar 

  5. Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935

    Article  PubMed  CAS  Google Scholar 

  6. Ouchi N, Kihara S, Arita Y et al (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057–1063

    PubMed  CAS  Google Scholar 

  7. Arita Y, Kihara S, Ouchi N et al (2002) Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105:2893–2898

    Article  PubMed  CAS  Google Scholar 

  8. Cruz M, Garcia-Macedo R, Garcia-Valerio Y et al (2004) Low adiponectin levels predict type 2 diabetes in Mexican children. Diabetes Care 27:1451–1453

    Article  PubMed  Google Scholar 

  9. Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599

    PubMed  CAS  Google Scholar 

  10. Baratta R, Amato S, Degano C et al (2004) Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 89:2665–2671

    Article  PubMed  CAS  Google Scholar 

  11. Kim OY, Koh SJ, Jang Y et al (2006) Plasma adiponectin is related to other cardiovascular risk factors in nondiabetic Korean men with CAD, independent of adiposity and cigarette smoking: cross-sectional analysis. Clin Chim Acta 370:63–71

    Article  PubMed  CAS  Google Scholar 

  12. Matsuzawa Y, Funahashi T, Nakamura T (1999) Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 892:146–154

    Article  PubMed  CAS  Google Scholar 

  13. Furuhashi M, Ura N, Higashiura K et al (2003) Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:76–81

    Article  PubMed  CAS  Google Scholar 

  14. Ouchi N, Kihara S, Arita Y et al (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476

    PubMed  CAS  Google Scholar 

  15. Okamoto Y, Kihara S, Ouchi N et al (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767–2770

    Article  PubMed  CAS  Google Scholar 

  16. Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946

    Article  PubMed  CAS  Google Scholar 

  17. Scherer PE, Williams S, Fogliano M et al (1995) A novel serum protein similar to C1q produced exclusively in adipocytes. J Biol Chem 270:26746–26749

    Article  PubMed  CAS  Google Scholar 

  18. Pajvani UB, Du X, Combs TP et al (2003) Structure-function studies of the adipocyte-secreted hormone Acrp3/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278:9073–9085

    Article  PubMed  CAS  Google Scholar 

  19. Stefan N, Vozarova B, Funahashi T et al (2002) Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 51:1884–1888

    Article  PubMed  CAS  Google Scholar 

  20. Okamoto Y, Arita Y, Nishida M et al (2000) An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32:47–50

    Article  PubMed  CAS  Google Scholar 

  21. Yamauchi T, Kamon J, Ito Y et al (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769

    Article  PubMed  CAS  Google Scholar 

  22. Civitarese AE, Jenkinson CP, Richardson D et al (2004) Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes. Diabetologia 47:816–822

    Article  PubMed  CAS  Google Scholar 

  23. Okamoto Y, Kihara S, Funahashi T et al (2006) Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci 110:267–278

    Article  PubMed  CAS  Google Scholar 

  24. Takahashi T, Saegusa S, Sumino H et al (2005) Adiponectin, T-cadherin and tumour necrosis factor-alpha in damaged cardiomyocytes from autopsy specimens. J Int Med Res 33:236–244

    PubMed  CAS  Google Scholar 

  25. Shibata R, Sato K, Pimentel DR et al (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med 11:1096–1103

    Article  PubMed  CAS  Google Scholar 

  26. Punthakee Z, Delvin EE, O’Loughlin J et al (2006) Adiponectin, adiposity and insulin resistance in children and adolescents. J Clin Endocrinol Metab 91:2119–2125

    Article  PubMed  CAS  Google Scholar 

  27. Chan DC, Watts GF, Ng TW et al (2006) Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. Diabetes Obes Metab 8:698–702

    Article  PubMed  CAS  Google Scholar 

  28. Lee S, Bacha F, Gungor N, Arslanian SA (2006) Racial differences in adiponectin in youth: relationship to visceral fat and insulin sensitivity. Diabetes Care 29:51–56

    Article  PubMed  CAS  Google Scholar 

  29. Nishizawa H, Shimomura I, Kishida K et al (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734–2741

    Article  PubMed  CAS  Google Scholar 

  30. Cnop M, Havel PJ, Utzschneider KM et al (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459–469

    PubMed  CAS  Google Scholar 

  31. Matsuda M, Shimomura I, Sata M et al (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487–37491

    Article  PubMed  CAS  Google Scholar 

  32. Chen H, Montagnani M, Funahashi T et al (2003) Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278:45021–45026

    Article  PubMed  CAS  Google Scholar 

  33. Mallamaci F, Zoccali C, Cuzzola F et al (2002) Adiponectin in essential hypertension. J Nephrol 15:507–511

    PubMed  CAS  Google Scholar 

  34. Adamczak M, Wiecek A, Funahashi T et al (2003) Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 16:72–75

    Article  PubMed  CAS  Google Scholar 

  35. Kazumi T, Kawaguchi A, Sakai K et al (2002) Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 25:971–976

    Article  PubMed  Google Scholar 

  36. Iwashima Y, Katsuya T, Ishikawa K et al (2004) Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43:1318–1323

    Article  PubMed  CAS  Google Scholar 

  37. Ouchi N, Ohishi M, Kihara S et al (2003) Association of hypoadiponectemia. Hypertension 42:231–234

    Article  PubMed  CAS  Google Scholar 

  38. Vita JA, Keaney JF Jr (2002) Endothelial function: a barometer for cardiovascular risk? Circulation 106:640–642

    Article  PubMed  Google Scholar 

  39. Fasshauer M, Klein J, Neumann S et al (2001) Adiponectin gene expression is inhibited by beta-adrenergic stimulation via proteins kinase A in 3T3-L1 adipocytes. FEBS Lett 507:142–146

    Article  PubMed  CAS  Google Scholar 

  40. Reaven GM (1988) Banting lecture 1988: role of insulin resistance in human disease. Diabetes 37:1595–1607

    Article  PubMed  CAS  Google Scholar 

  41. Murakami H, Ura N, Furuhashi M et al (2003) Role of adiponectin in insulin-resistant hypertension and atherosclerosis. Hypertens Res 26:705–710

    Article  PubMed  CAS  Google Scholar 

  42. Kondo H, Shimomura I, Matsukawa Y et al (2002) Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 51:2325–2328

    Article  PubMed  CAS  Google Scholar 

  43. Ohashi K, Ouchi N, Kihara S et al (2004) Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol 43:1195–1200

    Article  PubMed  CAS  Google Scholar 

  44. Hara K, Boutin P, Mori Y et al (2002) Genetic variation in the gene encoding adiponectin is associated with an increased risk type 2 diabetes in Japanese population. Diabetes 51:536–640

    Article  PubMed  CAS  Google Scholar 

  45. Yilmaz MI, Sonmez A, Kilic S et al (2005) The association of plasma adiponectin levels with hypertensive retinopathy. Eur J Endocrinol 152:233–240

    Article  PubMed  CAS  Google Scholar 

  46. Tsioufis C, Dimitriadis K, Chatzis D et al (2005) Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 96:946–951

    Article  PubMed  CAS  Google Scholar 

  47. Hong SJ, Park CG, Seo HS et al (2004) Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 13:236–242

    Article  PubMed  CAS  Google Scholar 

  48. Spranger J, Kroke A, Mohlig M et al (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228

    Article  PubMed  CAS  Google Scholar 

  49. Schulze MB, Shai I, Rimm EB et al (2005) Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54:534–539

    Article  PubMed  CAS  Google Scholar 

  50. Furuhashi M, Ura N, Moniwa N et al (2004) Possible impairment of transcardiac utilization of adiponectin in patients with type 2 diabetes. Diabetes Care 27:2217–2221

    Article  PubMed  Google Scholar 

  51. Maruyoshi H, Kojima S, Otsuka F et al (2005) Hypoadiponectinemia is associated with coronary artery spasm in men. Circ J 69:1154–1156

    Article  PubMed  Google Scholar 

  52. Kojima S, Funahashi T, Sakamoto T et al (2003) The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 89:667

    Article  PubMed  CAS  Google Scholar 

  53. Nystrom T, Nygren A, Sjoholm A (2005) Persistent endothelial dysfunction is related to elevated C-reactive protein (CRP) levels in Type II diabetic patients after acute myocardial infarction. Clin Sci (Lond) 108:121–128

    Article  Google Scholar 

  54. Choi KM, Lee KW, Kim SG et al (2005) Inflammation, insulin resistance, and glucose intolerance in acute myocardial infarction patients without a previous diagnosis of diabetes mellitus. J Clin Endocrinol Metab 90:175–180

    Article  PubMed  CAS  Google Scholar 

  55. Nakamura Y, Shimada K, Fukuda D et al (2004) Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 90:528–533

    Article  PubMed  CAS  Google Scholar 

  56. Kumada M, Kihara S, Sumitsuji S et al (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89

    Article  PubMed  CAS  Google Scholar 

  57. Lawlor DA, Davey Smith G, Ebrahim S et al (2005) Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 90:5677–5683

    Article  PubMed  CAS  Google Scholar 

  58. Xu A, Chan KW, Hoo RL et al (2005) Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280:18073–18080

    Article  PubMed  CAS  Google Scholar 

  59. Lawlor DA, Ebrahim S, Whincup P et al (2004) Sex differences in body fat distribution and carotid intima media thickness: cross sectional survey using data from the British regional heart study. J Epidemiol Community Health 58:700–704

    Article  PubMed  Google Scholar 

  60. Rothenbacher D, Brenner H, Marz W, Koenig W (2005) Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 26:1640–1646

    Article  PubMed  CAS  Google Scholar 

  61. von Eynatten M, Schneider JG, Humpert PM et al (2006) Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men. J Am Coll Cardiol 47:2124–2126

    Article  CAS  Google Scholar 

  62. Wolk R, Berger P, Lennon RJ et al (2003) Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation 108:2206–2211

    Article  PubMed  Google Scholar 

  63. Pischon T, Girman CJ, Hotamisligil GS et al (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737

    Article  PubMed  CAS  Google Scholar 

  64. George J, Patal S, Wexler D et al (2006) Circulating adiponectin levels predict outcome in patients with severe congestive heart failure. Heart DOI:10.1136/hrt.2005.083345

  65. Kistorp C, Faber J, Galatius S et al (2005) Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112:1756–1762

    Article  PubMed  CAS  Google Scholar 

  66. Qi Y, Takahashi N, Hileman SM et al (2004) Adiponectin acts in the brain to decrease body weight. Nat Med 10:524–529

    Article  PubMed  CAS  Google Scholar 

  67. Yang WS, Lee WJ, Funahashi T et al (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815–3819

    Article  PubMed  CAS  Google Scholar 

  68. Chamorro A (2004) Role of inflammation in stroke and atherothrombosis. Cerebrovasc Dis 17[Suppl 3]:1–5

    Article  CAS  Google Scholar 

  69. Diez JJ, Iglesias P (2003) The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148:293–300

    Article  PubMed  CAS  Google Scholar 

  70. Soderberg S, Stegmayr B, Stenlund H et al (2004) Leptin, but not adiponectin, predicts stroke in males. J Intern Med 256:128–136

    Article  PubMed  CAS  Google Scholar 

  71. Chen MP, Tsai JC, Chung FM et al (2005) Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 25:821–826

    Article  PubMed  CAS  Google Scholar 

  72. Efstathiou SP, Tsioulos DI, Tsiakou AG et al (2005) Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 36:1915–1919

    Article  PubMed  CAS  Google Scholar 

  73. Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599

    PubMed  CAS  Google Scholar 

  74. Spiegelman BM (1998) PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507–514

    Article  PubMed  CAS  Google Scholar 

  75. Marx N, Duez H, Fruchart JC, Staels B (2004) Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94:1168–1178

    Article  PubMed  CAS  Google Scholar 

  76. Maeda N, Takahashi M, Funahashi T et al (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094–2099

    Article  PubMed  CAS  Google Scholar 

  77. Phillips SA, Ciaraldi TP, Kong AP et al (2003) Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52:667–674

    Article  PubMed  CAS  Google Scholar 

  78. Jung HS, Youn BS, Cho YM et al (2005) The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 54:314–320

    Article  PubMed  CAS  Google Scholar 

  79. Kawai T, Takei I, Oguma Y et al (1999) Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 48:1102–1107

    Article  PubMed  CAS  Google Scholar 

  80. Chu CS, Lee KT, Lee MY et al (2006) Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 97:646–650

    Article  PubMed  CAS  Google Scholar 

  81. Samaha FF, Szapary PO, Iqbal N et al (2006) Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 26:624–630

    Article  PubMed  CAS  Google Scholar 

  82. Abbasi F, Chang SA, Chu JW et al (2006) Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. Am J Physiol Regul Integr Comp Physiol 290:R139–R144

    PubMed  CAS  Google Scholar 

  83. Kim SG, Ryu OH, Kim HY et al (2006) Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. Eur J Endocrinol 154:433–440

    Article  PubMed  CAS  Google Scholar 

  84. Rasouli N, Yao-Borengasser A, Miles LM et al (2006) Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 290:E42–E46

    Article  PubMed  CAS  Google Scholar 

  85. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ (2005) Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 46:773–778

    Article  PubMed  CAS  Google Scholar 

  86. Miyazaki Y, Murakami H, Hirata A et al (1998) Effects of the angiotensin converting enzyme inhibitor temocapril on insulin sensitivity and its effects on renal sodium handling and the pressor system in essential hypertensive patients. Am J Hypertens 11:962–970

    Article  PubMed  CAS  Google Scholar 

  87. Lind L, Berne C, Lithell H (1995) Prevalence of insulin resistance in essential hypertension. J Hypertens 13:1457–1462

    PubMed  CAS  Google Scholar 

  88. Koh KK, Quon MJ, Han SH et al (2004) Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110:3687–3692

    Article  PubMed  CAS  Google Scholar 

  89. Agata J, Nagahara D, Kinoshita S et al (2004) Angiotensin II receptor blocker prevents increased arterial stiffness in patients with essential hypertension. Circ J 68:1194–1198

    Article  PubMed  CAS  Google Scholar 

  90. Nowak L, Adamczak M, Wiecek A (2005) Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 18:1470–1475

    Article  PubMed  CAS  Google Scholar 

  91. Sonmez A, Dogru T, Tasci I et al (2006) The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia. Clin Endocrinol (Oxf) 64:567–572

    Article  CAS  Google Scholar 

  92. Chu CS, Lee KT, Lee MY et al (2006) Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia. Acta Cardiol 61:263–269

    Article  PubMed  Google Scholar 

  93. Gannage-Yared MH, Azar RR, Amm-Azar M et al (2005) Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 54:947–951

    Article  PubMed  CAS  Google Scholar 

  94. Chu CS, Lee KT, Lee MY et al (2006) Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 97:646–650

    Article  PubMed  CAS  Google Scholar 

  95. Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106:171–176

    Article  PubMed  CAS  Google Scholar 

  96. Furuhashi M, Ura N, Murakami H et al (2002) Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle. J Endocrinol 174:321–329

    Article  PubMed  CAS  Google Scholar 

  97. Ohashi K, Kihara S, Ouchi N et al (2006) Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47:1108–1116

    Article  PubMed  CAS  Google Scholar 

  98. Gavrila A, Peng CK, Chan JL et al (2003) Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 88:2838–2843

    Article  PubMed  CAS  Google Scholar 

  99. Shea SA, Hilton MF, Orlova C et al (2005) Independent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab 90:2537–2544

    Article  PubMed  CAS  Google Scholar 

  100. Monzavi R, Dreimane D, Geffner ME et al (2006) Improvement in risk factors for metabolic syndrome and insulin resistance in overweight youth who are treated with lifestyle intervention. Pediatrics 117:e1111–e1118

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine Department Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy

    R. Tarquini & G. Laffi

  2. Heart and Vessel Department Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy

    C. Lazzeri & G. F. Gensini

  3. Internal Medicine Department Azienda Ospedaliero-Universitaria Careggi, University of Florence, Viale Morgagni 85, I-50184, Florence, Italy

    R. Tarquini

Authors
  1. R. Tarquini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Lazzeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Laffi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. F. Gensini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Tarquini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tarquini, R., Lazzeri, C., Laffi, G. et al. Adiponectin and the cardiovascular system: from risk to disease. Int Emergency Med 2, 165–176 (2007). https://doi.org/10.1007/s11739-007-0027-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-007-0027-9

Keywords

Search

Navigation